These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1153148)

  • 1. Use of medroxyprogesterone acetate to prevent menopausal symptoms.
    Bullock JL; Massey FM; Gambrell RD
    Obstet Gynecol; 1975 Aug; 46(2):165-8. PubMed ID: 1153148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women.
    Lobo RA; McCormick W; Singer F; Roy S
    Obstet Gynecol; 1984 Jan; 63(1):1-5. PubMed ID: 6318170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
    Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral medroxyprogesterone in the treatment of postmenopausal symptoms.
    Schiff I; Tulchinsky D; Cramer D; Ryan KJ
    JAMA; 1980 Sep; 244(13):1443-5. PubMed ID: 6775094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis.
    Dennerstein GJ
    J Reprod Med; 1986 Sep; 31(9):801-3. PubMed ID: 2945926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
    Chandeying V; Sangthawan M
    J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of medroxyprogesterone acetate for relief of climacteric symptoms.
    Morrison JC; Martin DC; Blair RA; Anderson GD; Kincheloe BW; Bates GW; Hendrix JW; Rivlin ME; Forman EK; Propst MG; Needham R
    Am J Obstet Gynecol; 1980 Sep; 138(1):99-104. PubMed ID: 7416212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of the surgical menopause syndrome with depot medroxyprogesterone acetate and its objective evaluation testing the reaction of the anterior pituitary gland to stimulation with gonadotropin-releasing hormone].
    Boschitsch E; Gitsch E; Spona J
    Wien Klin Wochenschr; 1983 Oct; 95(20):718-24. PubMed ID: 6229096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation into the climacteric in Nigerians.
    Aina AO
    J Med Assoc Thai; 1992 Mar; 75(3):168-72. PubMed ID: 1506795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of estrogen, luteinizing hormone, and follicle stimulating hormone following castration and estradiol implant.
    Hunter DJ; Julier D; Franklin M; Green E
    Obstet Gynecol; 1977 Feb; 49(2):180-5. PubMed ID: 834401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient.
    Weinstein L
    Obstet Gynecol; 1987 Jun; 69(6):929-32. PubMed ID: 3574823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.
    Hargrove JT; Maxson WS; Wentz AC; Burnett LS
    Obstet Gynecol; 1989 Apr; 73(4):606-12. PubMed ID: 2538787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of depo-provera in teens.
    Khoiny FE
    J Pediatr Health Care; 1996; 10(5):195-201. PubMed ID: 8920351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled, crossover trial of propranolol as treatment for menopausal vasomotor symptoms.
    Alcoff JM; Campbell D; Tribble D; Oldfield B; Cruess D
    Clin Ther; 1981; 3(5):356-64. PubMed ID: 7471131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
    Cedars MI; Lu JK; Meldrum DR; Judd HL
    Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma.
    Aslaksen K; Frankendal B
    Acta Obstet Gynecol Scand; 1982; 61(5):423-8. PubMed ID: 6760653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.
    Barnes RB; Roy S; Lobo RA
    Obstet Gynecol; 1985 Aug; 66(2):216-9. PubMed ID: 2991832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.